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Upregulation of cyclin Dl, a key regulator of cell cycle, by elevated p-catenin through the disruption of Wnt signaling pathway is often seen in colon cancer and breast cancer. Cyclin Dl overexpression is also reported in about 25% of human prostate cancer where only about 5% mutation in p-catenin is found. Human AXIN2 and other components in the Wnt signaling pathway may also contribute to cyclin Dl elevation. To test this hypothesis, we checked 115 prostate cancer patients their cyclin Dl expression level in primary tumor cells using immunohistochemical staining by cyclin Dl antibody. Total number of 43 tumor samples were identified with strong and moderate cyclin Dl overexpression. Mutational analysis by DHPLC method revealed novel mutations in exon 1 of AXIN2 gene (SerSOPro and SerSlPro) and exon 3 of P-catenin (Asp32Gly and Thr41Ala). Expression contructs of AXIN2 containing these mutations have been generated and functional roles of these mutant proteins in Wnt signaling pathway are being investigated.
Introduction
Accumulation of genetic changes affecting the expression and function of critical genes involved in cell proliferation and apoptosis is thought to drive malignant transformation and cancer progression. Such genetic alterations are poorly understood in prostate cancer. Analysis of such affected genes might confer deeper insight into these processes and might lead to better therapeutic strategies. The Wnt signaling pathway is a very conserved pathway and plays an important role in early development and tumorigenesis. Wnt regulates developmental and oncogenic processes through its downstream effector, p-catenin. Elevated p-catenin in the cytoplasm is translocated into the nucleus where it activates target genes such as cyclin Dl, c-myc, etc., resulting in cancer. The upregulation of cyclin Dl, a key regulator of cell cycle, by elevated P-catenin through the disruption of the Wnt signaling pathway is often seen in colon cancer and breast cancer. Cyclin Dl overexpression is also reported in about 25% of human prostate cancer where only -5% mutation in P-catenin is found. It suggests that other components in the Wnt signal pathway may also contribute to cyclin Dl overexpression. The human AXIN2 gene cloned in our laboratory was mutated in about 30% of colorectal cancer with defective DNA mismatch repair (MMR). Our investigations show that this gene is involved in the Wnt signal pathway since mutant AXIN2 elevates nuclear P-catenin levels. Therefore the underlying hypothesis driving this project is that the mutant human AXIN2 gene is involved in prostate carcinogenesis by upregulating cytosolic p-catenin that leads to cyclin Dl overexpression in the nucleus. Prostate tumors with elevated expression of cyclin Dl are more likely to harbor AXIN2, AXINl and p-catenin mutations that may result in higher expression of p-catenin. The specific aims of this proposal are to: (1) characterize the expression of cyclin Dl in more than 100 collected prostate cancer samples; (2) screen for mutations in human AXIN2, AXINl and P-catenin genes in samples with cyclin Dl overexpression; (3) construct mutant AXIN2 expression plasmids to elucidate its functional role in cell proliferation and apoptosis. We report here completion of characterization of prostate tumors with cyclin Dl overexpression using immunohistochemical staining method and identification of novel mutations of AXIN2 and p-catenin in these tumors by DHPLC.
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Analysis of Human AXIN2 and Other Wnt Signal Pathway Genes in Human Prostate Cancer (Award No. DAMD17-02-1-0092)
Cyclin Dl is a member of a large family of cyclins. It forms complexes with cyclindependent kinases CDK4 and CDK6 to phosphorylate retinoblastoma protein allowing cells to proceed to S-phase (1-3). Deregulated overexpression of Cyclin Dl protein is frequently observed in breast, head and neck, colon, skin, and urinary bladder tumors (4) (5) (6) . However, little is knovm concerning the expression status of cyclin Dl in primary prostate carcinomas. We collected 115 prostate cancer patients' paraffm-embedded tissue blocks and corresponding H&E slides from Mayo Clinic Tissue Registry. H&E slides were used to validate the presence of infilfrating carcinoma cells and score the pathological stage of these cells on the paraffm-embedded specimens as previously descrbed (7) . For each patient, one tissue block was selected for the immunostaining study. A mouse monoclonal anti-human cyclin Dl antibody (Clone DCS-6, DAKO) was used for immunohistochemistry (8) . The specificity of the antibody was verified by immunoblotting using prostate benign and carcinoma cell lines BPH-1, LnCap, DU145 and PC3. We optimized staining procedures concerning antibody dilutions and specific treatment of the tissue sections using paraffin-embedded specimens of breast carcinomas. The staining pattern of this antibody is predominantly nuclear. Cytoplasmic staining in the absence of nuclear staining is considered negative. We categorized 115 cases into three groups based on the cyclin Dl staining intensity. The first group displays the strongest nuclear staining when compared with neighboring normal cells (Figure la) . The second group shows moderate intensity of nuclear cyclin Dl staining (Figure lb) . These two groups account roughly 37% of the cases ( Table 1 ). The third group includes all cases that either have exfremely weak or negative cyclin Dl staining ( Figure Ic) . Cases that have few tumor cells with positive staining are also considered negative. In majority of the cases (40 out of 43) with cyclin Dl positive staining, the pattern is extremely focal and represent only less than 10% of the carcinoma cells. The focal staining is usually observed in infilfrating carcinoma vnth clusters of very small glandular tubules. No apparent association is found between cyclin Dl staining and the Gleason grade of these 115 primary prostatic tumors (p= 0.545). We are currentiy examining 20 metastatic prostatic tumor samples and final data and analysis including these samples will be presented in the final report. We screened for mutations of AXIN2 and exon 3 oi fi-catenin in isolated genomic DNA from 43 tissue samples that showed strong and moderate cyclin Dl staining stated in Table 1 , using highly accurate and cost-effective DHPLC method. The primers and procedures used in the PCR amplification and DHPLC analysis are as described in the original proposal. A novel single nucleotide mutation T148C was found in the first exon of AXIN2 in 2 patients and another one T241C, also in the first exon, was detected in 1 patient (Figure 2 (a) and 2 (b) ). Both mutations cause amino acid change from serine to proline at positions 50 and 81, respectively. These two mutations occur in the APC binding domain of AXIN2 (9) and eliminate two phosphorylation sites that may have fiinctional importance in Wnt signaling. The 12-bp deletion mutation in AXIN2 (see the original proposal) were also detected in two patients (data not shown). Two different mutations were also found in the third exon of p-catenin, A95G and A121G, in two patients (Figure 2 (c) and 2 (d) ). They switch amino acid from aspartic acid (32) to glycine and threonine (41) to alanine, respectively. They are present in the N-terminus that regulates the stability of P-catenin (10) . These mutations in AXIN2 and fi-catenin do not co-exist in the same patient. Our current data indicates that AXIN2 and /i-catenin mutations are infrequent in primary prostate carcinomas (<8%).
We generated two different expression constructs of mutant AXIN2 with the 12-bp deletion, SerSOPro and SerSlPro in both pCMV and pTRE vectors. The pCMV expression construct can be used to transfect a wide spectrum of cell lines to constitutively express AXIN2 wild-type and mutant protein. The advantage of pTRE construct is that expression of AXIN2 is controllable by doxycycline, a chemical derivative of tetracycline, in Tet-On and Tet-Off cell lines (11) . Using these two expression systems we observed that axin2 protein can be highly expressed in 293T, COS-7 and HeLa cells and both wild-type and mutant are localized in the cytoplasm. We are currently in the process of analyzing the fimction of the mutant AXIN2 in cell proliferation and apoptosis using these two expression systems by performing transient and stable transfections. To summarize, we have completed Task 1, Task 3 and Most part of Task 2 as stated in the Statement of Work in the original proposal. The delay to accomplish Task 2 is due to the process of change of PI of this award in September in 2002 from previous PI Dr. Xiangyang Dong to me. We are still screening for AXINl mutations (Task 2) in these selected primary prostate tumors. We will focus on Task4 and accelerate the remaining work in tiie second calendar year of this award.
Note: This report includes around 50% contribution of experimental work of Dr. Xiangyang Dong. Change of PI from Dr. Xiangyang Dong to Dr. Xianshu Wang for this award was completed in September, 2002.
Conclusions
Publications on the status of cyclin Dl expression in primary prostate carcinomas are rare (12) . The number of tumor samples and antibody used in cyclin Dl staining is of great importance in obtaining reliable data. We collected a large number of paraffin-embedded tissue blocks and selected a mouse monoclonal antibody (Clone DCS-6, DAKO) that has been demonstrated to work well in immunohistochemical staining (4) (5) (6) .
The immunostaining results showed that cyclin Dl overexpression occurred in about onethird of the prostate tumors we examined. The frequency is only half of the 60% rate observed in breast cancer. Even in tumors with increased expression of cyclin Dl, positive staining of tumor cells is confined and focal, consistent with the heterogeneous nature of prostate cancer. The mutation rate of AXIN2 and j^-catenin is also lower than that in colon cancer indicating that genetic alterations contributing to the majority of nonMendelian inheritance of prostate cancer are very likely the common low penetrant alleles. Genetic components in pathways other than Wnt signaling, such as DNA damage and repair signaling pathway, might also play critical roles in prostatic carcinogenesis. Our future work will focus on validating the significance of these mutations by screening a larger group of prostate cancer patients and normal control population. In the meantime, we are concentrating on finding the functional implications of these mutations in cell growth, proliferation and apoptosis.
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